Menu Close

Trending

Data backs AZ’s Wilson disease drug, but with a question mark
Fujifilm acquires AI tech to improve fertility treatment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
New countries stockpile antiviral TPOXX as monkeypox outbreak continues
Biogen and Happify partner on digital support for MS patients

Loxo Oncology

Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib

Market Access/ News/ News/ News/ Oncology

Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib

, , , , , , 0 Comment

Eli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter

X
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
https://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
x-ray lung cancer

News/ News/ Oncology/ Top stories

Relief for Lilly as drug from $8bn Loxo deal clears pivotal trial

, , , , , , , 0 Comment

Eli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for

X
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trial
https://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
ASCO 2018 imagery

ASCO 2018/ Oncology/ Views & Analysis/ Views and analysis

ASCO 2018 Preview – what to expect from this year’s conference

, , , , , , , , , , , 0 Comment

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the

X
ASCO 2018 Preview – what to expect from this year’s conference
https://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/

Login

CONTINUE TO SITE >
X
Close in 10 seconds